Press Releases
September 17, 2025
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
September 11, 2025
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
September 9, 2025
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
August 28, 2025
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
August 24, 2025
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
August 8, 2025
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
July 27, 2025
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
July 8, 2025
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
June 20, 2025
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
June 5, 2025